ReviewCellular and molecular life sciences : CMLS2020
The mechanisms of pathological extramedullary hematopoiesis in diseases.
Review in Cellular and molecular life sciences : CMLS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.Annals of hematology · 2026Pooled it
- Extramedullary haematopoiesis in patients with transfusion dependent β-thalassaemia (TDT): a systematic review.Annals of medicine · 2022Pooled it
- Nitrogen Dioxide Inhalation Disrupts Bone Marrow Hematopoiesis by Inducing Stage-Specific Developmental Blockage in Erythroid and Granulocytic Lineages in Mice.Environment & health (Washington, D.C.) · 2026Article
- Article
- Intermittent oral administration of iron oxide nanoparticles modulates iron homeostasis, hematological, inflammatory, and organ-specific responses in iron-deficient rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Enlarged splenic volume predicts poor survival and is associated with inflammatory imbalance in patients with diffuse large B-cell lymphoma.Blood research · 2026Article
- HSPCs and TScience advances · 2026Article
- CD71BMC nephrology · 2026Article
- Galectin-9Aging cell · 2026Article
- Targeting erythroid progenitor cell metabolism to enhance cancer immunotherapy.NPJ precision oncology · 2026Review
- Dysplastic Megakaryocytes in a Gallbladder Neck Lymph Node in a Patient With Essential Thrombocythemia: A Case Report.Case reports in hematology · 2026Article
- Extramedullary Hematopoiesis in the Cerebral Dura Resulting in Fatal Brain Herniation in a Patient With Secondary Myelofibrosis: A Case Report.Case reports in hematology · 2026Article
- Histological characterization of major internal organs in infant common marmosets (Callithrix jacchus).PloS one · 2026Article
- Case Report: life-threatening haemothorax due to extramedullary haematopoiesis in a patient with Beta-thalassaemia major.Frontiers in medicine · 2026Article
- CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.Journal of cellular and molecular medicine · 2025Article
- A capsular myofibroblastic niche maintains hematopoietic stem cells in the spleen.The EMBO journal · 2025Article
- Article
- Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations.Cancers · 2025Article
- Extramedullary Hematopoiesis Presenting as Pleural Thickening in a Patient With Choroidal Melanoma.Cureus · 2025Article
- tMCS Causing Myocardial Extramedullary Hematopoiesis Secondary to Massive Hemolysis.JACC. Case reports · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Extramedullary hematopoiesis (EMH) is the expansion and differentiation of hematopoietic stem and progenitor cells outside of the bone marrow. In postnatal life, as a compensatory mechanism for ineffective hematopoiesis of the bone marrow, pathological EMH is triggered by hematopoietic disorders, insufficient hematopoietic compensation, and other pathological stress conditions, such as infection, advanced tumors, anemia, and metabolic stress. Pathological EMH has been reported in many organs, and the sites of pathological EMH may be related to reactivation of the embryonic hematopoietic structure in these organs. As a double-edged sword (blood and immune cell supplementation as well as clinical complications), pathological EMH has been widely studied in recent years. In particular, pathological EMH induced by late-stage tumors contributes to tumor immunosuppression. Thus, a deeper understanding of the mechanism of pathological EMH may be conducive to the development of therapies against the pathological processes that induce EMH. This article reviews the recent progress of research on the cellular and molecular mechanisms of pathological EMH in specific diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.